Related Experiment Video

Updated: May 29, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

MicroRNA-mediated drug resistance in breast cancer

Kristy R Kutanzi, Olga V Yurchenko, Frederick A Beland

    Clinical Epigenetics
    |September 28, 2011
    PubMed

    Insights

    MicroRNAs regulate chemoresistance in breast cancer by controlling genes involved in drug resistance. Targeting microRNAs offers a potential new strategy to overcome treatment resistance.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Chemoresistance is a significant obstacle in breast cancer treatment.
    • Mechanisms include altered drug metabolism, impaired cellular responses, and genetic/epigenetic changes.
    • MicroRNAs (miRNAs) are emerging as key regulators of chemoresistance.

    Purpose of the Study:

    • To review the role of microRNAs in regulating chemoresistance in breast cancer.
    • To highlight potential therapeutic targets for reversing miRNA-mediated drug resistance.

    Main Methods:

    • Literature review of studies investigating microRNAs and chemoresistance.
    • Analysis of genetic and epigenetic mechanisms of drug resistance.
    • Identification of microRNA regulatory networks in cancer cells.

    Main Results:

    • MicroRNAs act as master regulators of genes involved in chemoresistance pathways.
    • Dysregulation of specific miRNAs contributes to various resistance mechanisms.
    • Targeting miRNAs can potentially reverse drug resistance.

    Conclusions:

    • MicroRNAs play a critical role in mediating chemoresistance in breast cancer.
    • MicroRNA-based therapies, combined with chemotherapy, show promise for treating drug-resistant breast cancers.
    • Further research into miRNA-mediated resistance could lead to novel clinical strategies.

    More Related Videos

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

    Published on: February 21, 2014

    Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization06:01

    Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

    Published on: June 7, 2016

    Related Concept Videos

    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Mechanism of Antibiotic Resistance in MRSA01:25

    Mechanism of Antibiotic Resistance in MRSA

    Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
    Clinical Significance of Antibiotic Resistance01:25

    Clinical Significance of Antibiotic Resistance

    Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...